5 Best Cancer Stocks to Buy for the Long Term

3. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 71

Gilead Sciences, Inc. (NASDAQ:GILD) is among the best cancer stocks to invest in.

TheFly reported on May 7 that GILD revised its fiscal 2026 outlook, now expecting adjusted earnings per share between a loss of $1.05 and a loss of $0.65, compared with prior guidance of $8.45 to $8.85 and below consensus estimates of $8.65. The updated forecast reflects a substantial downward adjustment driven by roughly $11.5 billion in acquired in-process research and development charges, along with financing costs tied to recent transactions involving Arcellx, Ouro Medicines, and Tubulis. Management indicated that these factors significantly impacted both GAAP and non-GAAP earnings expectations for the year.

Separately, on April 29, in a pivotal regulatory development, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration had formally accepted its New Drug Application for a once-daily single-tablet regimen combining bictegravir 75 mg and lenacapavir 50 mg.

The investigational therapy is intended for adults living with HIV who are already virologically suppressed. The agency has also granted the application priority review status and set a target action date of August 27, 2026, under the Prescription Drug User Fee Act timeline. This designation shortens the review period and signals potential regulatory importance for the proposed combination treatment.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company based in Foster City that has expanded from antivirals into oncology. Through acquisitions like Kite Pharma and Immunomedics, it focuses on CAR-T cell therapies and antibody drug conjugates to treat blood and breast cancers.